Get the Stockscreener App
42.49
1.58%
-0.68
After Hours:
42.49
Zenas Biopharma Inc stock is traded at $42.49, with a volume of 134.33K.
It is down -1.58% in the last 24 hours and up +4.84% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$43.17
Open:
$43.04
24h Volume:
134.33K
Relative Volume:
0.31
Market Cap:
$2.28B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+17.54%
1M Performance:
+4.84%
6M Performance:
+318.62%
1Y Performance:
+322.79%
1-Day Range:
$41.67
$43.17
1-Week Range:
$36.16
$44.60
52-Week Range:
$5.83
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
42.49 | 2.32B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Zenas BioPharma : Corporate Presentation - marketscreener.com
Is Zenas BioPharma Inc. stock attractive after correctionFibonacci Extensions & Target Triple-Digit Stock Opportunities - Bollywood Helpline
Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher - simplywall.st
Zenas BioPharma (NASDAQ:ZBIO) Hits New 52-Week HighWhat's Next? - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Trading 8.9% HigherShould You Buy? - MarketBeat
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next - ts2.tech
Zenas Biopharma stock reaches all-time high of 41.67 USD - Investing.com
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says - marketscreener.com
Wedbush Reiterates Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to NASDAQ Biotechnology Index - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-21 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse
How interest rate cuts could boost Zenas BioPharma Inc. stockRecession Risk & Weekly Hot Stock Watchlists - ulpravda.ru
Zenas BioPharma approves 2026 inducement plan - MSN
Can Zenas BioPharma Inc. stock reach $100 price target2025 Risk Factors & Short-Term High Return Ideas - Улправда
Why Zenas BioPharma Inc. stock remains on buy listsJuly 2025 Technicals & Stepwise Swing Trade Plans - Улправда
Winners Losers: What sentiment indicators say about Zenas BioPharma Inc. stock2025 Big Picture & Daily Entry Point Trade Alerts - Улправда
Growth Value: How interest rate cuts could boost Zenas BioPharma Inc. stockShare Buyback & Weekly High Return Stock Forecasts - Улправда
Zenas Biopharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Insider Trends: How interest rate cuts could boost Zenas BioPharma Inc. stock - Улправда
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Is Zenas BioPharma Inc. stock resilient to inflationJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber
What insider trading reveals about Zenas BioPharma Inc. stockJuly 2025 Chart Watch & Low Risk Entry Point Guides - DonanımHaber
New Highs: How interest rate cuts could boost Zenas BioPharma Inc. stockTrade Risk Summary & Risk Controlled Stock Alerts - Улправда
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Earnings Report: Is Zenas BioPharma Inc stock a bargain at current levelsJuly 2025 Earnings & Free Community Supported Trade Ideas - moha.gov.vn
Orelabrutinib’s SLE Phase 2b Success Could Be A Game Changer For Zenas BioPharma (ZBIO) - Sahm
H.C. Wainwright reiterates Buy rating on Zenas Biopharma stock amid competitor setback - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Trading 6.7% HigherTime to Buy? - MarketBeat
Zenas BioPharma Shares Surge Amid Promising Drug Trials - TipRanks
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential - TipRanks
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside - TipRanks
Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod - Indian Pharma Post
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Yahoo Finance
Zenas BioPharma (ZBIO): Reassessing a Rich Valuation After Positive Orelabrutinib Lupus Trial Milestones - Sahm
Zenas BioPharma Approves 2026 Inducement Plan - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 9.9%Should You Sell? - MarketBeat
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How - GuruFocus
InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib - TipRanks
Innocare Pharma announces achievement of primary endpoint in phase 2b study of orelabrutinib - marketscreener.com
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - The Manila Times
Zenas Prepares For INDIGO Phase 3 Readout—Reinstating Buy Rating (ZBIO) - Seeking Alpha
Zenas BioPharma Says Partner InnoCare's Phase 2b Orelabrutinib Study in Systemic Lupus Erythematosus Meets Primary Endpoint - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
IgG4-related Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht - The Globe and Mail
Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):